Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Effect of in Vitro Haemolysis on Serum High Sensitivity Troponin T Measurements From Patients in Accident & Emergency

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03439605
Recruitment Status : Completed
First Posted : February 20, 2018
Last Update Posted : February 20, 2018
Sponsor:
Information provided by (Responsible Party):
Poole Hospital NHS Foundation Trust

Brief Summary:
This study will be investigating how a common blood test for identifying heart damage (Troponin T) is affected by red blood cell damage in the blood sample (Haemolysis). It is already known that damage to the red blood cells during or after blood sample collection can cause falsely low test results however the exact amount is not clear. Some previous studies suggest that a much higher amount of red blood cell damage could be allowable when reporting the test results. This study will mimic the type of red blood cell damage that occurs in the hospital and determine what degree of damage or 'haemolysis' causes a significant reduction in the test result and therefore determine an allowable limit for safely reporting the test result. The results of this study may help provide an evidence based approach to improving current practice and may lead to fewer rejected blood samples, fewer repeat tests, improved A&E treatment times, general cost savings and an improved service to patients.

Condition or disease
Troponin T Hemolysis

Detailed Description:

This study will be investigating how a common blood test for identifying heart damage (Troponin T) is affected by red blood cell damage in the blood sample (Haemolysis). It is already known that damage to the red blood cells during or after blood sample collection can cause falsely low test results however the exact amount is not clear. Some previous studies suggest that a much higher amount of red blood cell damage could be allowable when reporting the test results. This study will mimic the type of red blood cell damage that occurs in the hospital and determine what degree of damage or 'haemolysis' causes a significant reduction in the test result and therefore determine an allowable limit for safely reporting the test result. The results of this study may help provide an evidence based approach to improving current practice and may lead to less rejected blood samples, fewer repeat tests, improved treatment times in Accident and Emergency (A&E), general cost savings and an improved service to patients.

This study will be conducted as a Masters research project in Biomedical sciences (Clinical Biochemistry) as well as providing evidence to evaluate current laboratory practice. Participants attending Poole Hospital accident and emergency who are already having blood samples taken for the heart damage blood test, high sensitivity Troponin T (hs-cTnT), are chosen for this study. As the participants are already having the hs-cTnT blood test performed it means the investigators will not be determining any new information about them from the tests and they are also the population that the results of the study will benefit.

Whilst the participants are having the routine blood samples taken for their medical investigation, an extra two blood samples will be collected (a maximum of 9 ml; less than two teaspoons) following verbal permission. Only patients with the capacity to give verbal consent will be included in the study and then their blood will only be taken once. The extra blood samples will be labelled with the time and date of collection (to ensure stability when analysing). No patient identifying information will be written on the samples and they will be sent to the laboratory in a separate bag from the routine specimens to ensure anonymity.

Once received in the laboratory, one of the study samples will be analysed for hs-cTnT and haemolysis index (a measured value that equates to the amount of haemoglobin in the sample and therefore red blood cell damage). The results from these initial tests will determine if the hs-cTnT and haemolysis are within the desired range for the study.

If the sample meets the requirements for the study, a sample specific haemolysate (Haemolysed serum) will be created from the second sample. Using both samples, varying controlled degrees of haemolysis will be created and then tested for hs-cTnT. The results from the varying degrees of haemolysis will be compared to the original unhaemolysed result to determine whether a significant change in the result has occurred.

Null hypotheses:

  • There is no significant difference in hs-cTnT results between baseline and up to 100 haemolysis index. There is a significant difference in hs-cTnT results between baseline and all haemolysis index levels greater than 100.
  • There is no significant difference in mean percentage change of hs-cTnT up to 100 Haemolysis index and there is a significant difference in mean percentage change of hs-cTnT at all Haemolysis levels greater than 100 haemolysis index.

Layout table for study information
Study Type : Observational
Actual Enrollment : 61 participants
Observational Model: Cohort
Time Perspective: Cross-Sectional
Official Title: Investigation Into the Effect of in Vitro Haemolysis on Serum High Sensitivity Troponin T Measurement, and the Determination of an Acceptable Haemolysis Index Limit
Actual Study Start Date : September 9, 2017
Actual Primary Completion Date : December 6, 2017
Actual Study Completion Date : December 6, 2017



Primary Outcome Measures :
  1. The difference in measured hs-cTnT between baseline and the haemolysis groups. [ Time Frame: Day one ]

Secondary Outcome Measures :
  1. The Percentage change in hs-cTnT due to haemolysis at five groups of different troponin T levels. [ Time Frame: Day one ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   Child, Adult, Older Adult
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
Adult patients attending Poole emergency department having High Sensitivity Troponin T measurements performed on their blood as part of their medical investigations.
Criteria

Inclusion Criteria:

  • Adult patients attending Poole emergency department having High Sensitivity Troponin T measurements performed on their blood as part of their medical investigations.

Exclusion Criteria:

  • Serum samples with Haemolysis Index >20.
  • Serum High sensitivity Troponin T result <5 ng/l and >100 ng/l
  • Patients lacking capacity to give verbal consent.
  • Under 18 years of age.
  • Patient has previously been approached about this study.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03439605


Locations
Layout table for location information
United Kingdom
Poole Hospital NHSFT
Poole, Dorset, United Kingdom, BH15 2JB
Sponsors and Collaborators
Poole Hospital NHS Foundation Trust
Layout table for additonal information
Responsible Party: Poole Hospital NHS Foundation Trust
ClinicalTrials.gov Identifier: NCT03439605    
Other Study ID Numbers: SP170327
First Posted: February 20, 2018    Key Record Dates
Last Update Posted: February 20, 2018
Last Verified: February 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Poole Hospital NHS Foundation Trust:
Troponin-T
Haemolysis
Additional relevant MeSH terms:
Layout table for MeSH terms
Hemolysis
Pathologic Processes